Cómo los Pacientes Recién Diagnosticados con LMA Pueden Acceder a las Terapias Dirigidas Adecuadas
https://vimeo.com/1156890891 La Dra. Irum Khan explica por qué las pruebas genéticas oportunas son esenciales para acceder a las terapias dirigidas más efectivas para la leucemia mieloide aguda (LMA). Comparte pasos…
Acceso a Ensayos Clínicos en LMA: Cómo Superar las Principales Barreras de Atención
https://vimeo.com/1156890981 La Dra. Irum Khan, Profesora Asociada de Medicina en Hematología y Oncología en la Northwestern University Feinberg School of Medicine, explica por qué muchos pacientes con leucemia mieloide aguda…
How Newly Diagnosed AML Patients Can Access the Right Targeted Therapies
https://vimeo.com/1138340301 Dr. Irum Khan, Associate Professor of Medicine in Hematology & Oncology at Northwestern University Feinberg School of Medicine, explains why timely genetic testing is essential for accessing the most…
AML Clinical Trial Access: How You Can Overcome Key Barriers to Care
https://vimeo.com/1138340331 Dr. Irum Khan, Associate Professor of Medicine in Hematology & Oncology at Northwestern University Feinberg School of Medicine, sheds light on why many AML patients, especially those from marginalized…
Novel AML Therapy Use | Impact of Socioeconomic Status and Other Factors
https://vimeo.com/948960382 How do socioeconomic status and other factors impact novel acute myeloid leukemia (AML) therapy use? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses major factors that…
Underrepresented AML Clinical Trial Groups | What Solutions Are Underway?
https://vimeo.com/948960402 What steps are being taken to help underrepresented acute myeloid leukemia (AML) clinical trial groups? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses an important approach…
Why Is Post-Access Enrollment Vital in AML Clinical Trial Participation?
https://vimeo.com/948960428 For acute myeloid leukemia (AML) clinical trial participation, what makes post-access enrollment essential? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses factors that play into post-access…
What AML Clinical Trial Inequities Do Minority and Ethnic Groups Face?
https://vimeo.com/948960457 Do minority and ethnic groups face acute myeloid leukemia (AML) clinical trial inequities? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses research study results of NCI-designated…
What Are Key Acute Myeloid Leukemia Care Barriers and Solutions?
https://vimeo.com/948960484 What are key barriers and solutions to acute myeloid leukemia (AML) care? Expert Dr. Andrew Hantel from Dana-Farber Cancer Institute and Harvard Medical School discusses factors that create AML care barriers,…
Advancing Equity | Research Initiatives in AML Disparities Among Black and Latinx Populations
https://vimeo.com/925588114 What AML research efforts are underway to advance equity among Black and Latinx and populations? Expert Dr. Sara Taveras Alam from UTHealth Houston discusses initiatives that are working to improve AML…
AML Diagnosis Disparities | Factors Impacting Underrepresented Racial and Ethnic Groups
https://vimeo.com/925582366 What factors contribute to AML diagnosis disparities? Expert Dr. Sara Taveras Alam from UTHealth Houston discusses disparity factors in underrepresented patient groups and patient advice for newly diagnosed AML patients. [ACT]IVATION…
How Do AML Patients and Outcomes Differ by Population Groups?
https://vimeo.com/925579574 How do AML genetic and molecular subtypes vary by population groups, and what are the impacts? Expert Dr. Sara Taveras Alam from UTHealth Houston discusses AML characteristics that impact some population…